Guidelines published as an update on 2003 guidelines. About 8-9 pages. New data only Guidelines published as an update on 2003 guidelines. About 8-9 pages.

Slides:

Advertisements

Similar presentations

Slide #1 HIV Entry Inhibitors Trip Gulick, MD, MPH Director, Cornell HIV Clinical Trials Unit Associate Professor of Medicine Weill Medical College of.

Advertisements

Resistance Testing – Where Do I Start?

Summary of ARV prescribing guidelines in London These slides summarise the recommendations by the London HIV Consortium for prescribing antiretrovirals.

Salvage Antiretroviral Therapy Guiding Principles, Strategies and the Role of Resistance Testing.

Antiretroviral Treatment Highlights of the 11th Conference on Retroviruses and Opportunistic Infections (CROI) February 8-11, 2004; San Francisco, California.

Future Applications of Antiretroviral Agents in Development

Global HIV Resistance: The Implications of Transmission

Antiretroviral Activity and Tolerability of Reverset (D-d4FC), a New Fluoro-Cytidine Nucleoside Analog when used in Combination Therapy in Treatment- Experienced.

2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.

Pharmacokinetics of Saquinavir hard gel (Invirase) when combined with Atazanavir 8.11 D Prelutsky 1, P Salvato 2, R Falcon 3 1. Washington University School.

UK-CAB Jan05 BHIVA treatment guidelines UK-CAB - 28 Jan 2005 Simon Collins, HIV i-Base.

The Role of Maraviroc in Antiretroviral Therapy for Treatment-Experienced Patients Daniel R. Kuritzkes, MD Section of Retroviral Therapeutics Brigham and.

HIV-1 Resistance - Implications For Clinicians Joseph J. Eron Jr., MD Professor of Medicine University of North Carolina.

Background TMC278, a next-generation NNRTI, has demonstrated in-vitro activity against wild-type and NNRTI-resistant isolates 1 48-week results from an.

Predicting NNRTI Resistance – do polymorphisms matter? Nicola E Mackie 1, Lucy Garvey 1, Anna Maria Geretti 2, Linda Harrison 3, Peter Tilston 4, Andrew.

1 ARV Drug Resistance HAIVN Harvard Medical School AIDS Initiative in Vietnam.

TO EVALUATE EARLY ANTIVIRAL RESPONSE AND SAFETY OF A DUAL BOOSTED PROTEASE INHIBITORS REGIMEN INCLUDING LOPINAVIR/r (LPV) PLUS AMPRENAVIR (AMP) OR FORTOVASE.

1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.

HIV Principles in Primary Care and Triage of the HIV patient David Aymond, MD, AAHIVM.

1 RESIST Trials - Grade 3 or 4 AST, ALT or Total Bilirubin: Actions and Outcomes Action Taken: TPV/r N=748 CPI/r N=737 Total Number of Grade 3 or 4 ALT,

Highlights of the 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC) September 14-17, 2003; Chicago, Illinois Selected and summarized.

Update on HIV Therapy Elly T Katabira, FRCP Department of Medicine Makerere University Medical School Scaling up Treatment Programs: Issues, Challenges.

Combined PI and NNRTI Resistance Analysis of the Pooled DUET Trial: Towards a Regimen-Based Resistance Interpretation J. M. Schapiro, J. Vingerhoets, S.

Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.

12th Conference on Retroviruses and Opportunistic Infections February 22-25, 2005 Boston, Massachusetts, USA Poster No. 830 Hematological Benefit of Switching.

Prevention and Care Dr S Charalambous WHO guidelines.

INTRODUCTION A previous cohort study from our unit suggested a benefit for the use of efavirenz compared to nevirapine in a group of patients initiating.

Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.

Transmitted drug resistance Pat Cane. Questions What is the level of TDR and is it changing? Are we measuring TDR accurately? Are more sensitive methods.

Long Term Therapeutic Success of Etravirine in Switch and Naive Patients L.Bull, M.Bower, M.Nelson Chelsea and Westminster Hospital, London.

Clinical development programme for Second-Line treatment Anton Pozniak World AIDS Conference, July 2014.

HIV-1 Resistance - Implications For Clinicians Joseph J. Eron Jr., MD Professor of Medicine University of North Carolina.

Comparison of NNRTI vs NNRTI  ENCORE  EFV vs RPV –ECHO-THRIVE –STAR  EFV vs ETR –SENSE.

Design of the RESIST Study Program Dr Kevin Curry Boehringer Ingelheim, Bracknell, UK.

1/11/01 Pediatric trials for ARV experienced children Coleen K. Cunningham Epidemiology of treatment experience in pediatrics How does the smaller number.

Results From DUET-1 and DUET-2: ETR Plus DRV/RTV Associated With High Rates of Viral Suppression in Treatment-Experienced Patients This program is supported.

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Frequency HIV-1 Drug Resistance Mutations and.

Novel Classes of Antiretrovirals: Update on CCR5 Antagonists and Integrase Inhibitors This program is supported by an educational grant from.

HIV co-receptor tropism in treatment-naïve patients: impact on CD4 decline and subsequent response to HAART Laura Waters, Sundhiya Mandalia, Adrian Wildfire,

POWER 3 Study Confirms Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Patients Slideset on: Molina JM, Cohen C, Katlama C, et al.

ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.

First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.

Tipranavir/Ritonavir Superior to Comparator PI/Ritonavir at Week 48 in Multiclass-Experienced Patients Slideset on: Hicks CB, Cahn P, Cooper DA, et al.

High prevalence of antiretroviral drug resistance among HIV-infected pregnant women in Buenos Aires, Argentina Zapiola 1, D.M. Cecchini 2, S. Fernandez.

Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial

Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Etravirine in Treatment Experienced DUET-2 (TMC125-C216)

Switch to RPV-TDF-FTC from Ritonavir-boosted PI Regimen SPIRIT STUDY

Etravirine versus Protease Inhibitor in ARV-Experienced TMC 125-C227

Once Daily Etravirine versus Efavirenz in Treatment-Naive SENSE Trial

Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study

Etravirine in Treatment Experienced DUET-1 (TMC125-C206)

Darunavir/r versus Other PIs in Treatment Experienced POWER 1 and 2

Switching the NRTI Backbone to Tenofovir DF-Emtricitabine TOTEM

UK-CAB: Entry inhibitors and Immunology 3 June 2005

Changes in HIV-1 Co-receptor Tropism for Patients Participating in the Maraviroc MOTIVATE 1 and 2 Clinical Trials E van der Ryst and M Westby Pfizer Global.

St Stephen’s Centre, Chelsea & Westminster Hospital, United Kingdom

Why Dolutegravir? Daniel R. Kuritzkes, M.D.

Investigational Approaches to Antiretroviral Therapy

Drug-resistant human immunodefiency virus

Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens.

Changes in HIV-1 Co-receptor Tropism for Patients Participating in the Maraviroc MOTIVATE 1 and 2 Clinical Trials E van der Ryst and M Westby Pfizer Global.

Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.

Antiretroviral therapy for initial human immunodeficiency virus/AIDS treatment: critical appraisal of the evidence from over 100 randomized trials and.

Impact of Baseline NNRTI Mutations on the Virologic Response to TMC125 in the Phase III Clinical Trials DUET-1 and DUET-2 J Vingerhoets, A Buelens, M.

Switch to LPV/r monotherapy

Comparison of NNRTI vs NNRTI

ANTIRETROVIRAL RESISTANCE IN CLINICAL PRACTICE

INTRODUCTION OBJECTIVES METHODS RESULTS DISCUSSION

Presentation transcript:

Guidelines published as an update on 2003 guidelines. About 8-9 pages. New data only Guidelines published as an update on 2003 guidelines. About 8-9 pages. New data only Look at new “backbones of therapy?” Look at new “backbones of therapy?” Tenofovir/FTC O/D Tenofovir/FTC O/D New combinations of drugs; ie Abacavir/3TC O/D New combinations of drugs; ie Abacavir/3TC O/D Warn against combinations; ie Tenofovir/DDI… Warn against combinations; ie Tenofovir/DDI… Brian West: BHIVA Guidelines What’s new:

Tenofovir/FTC in preference to AZT/3TC, or even Kivexa? Tenofovir/FTC in preference to AZT/3TC, or even Kivexa? New drugs since 2003; new ways to build 1 st combo? New drugs since 2003; new ways to build 1 st combo? Still NNRTI as support to Combivir/Truvada/Kivexa in 1 st line, or maybe Fosamprenavir/Reyataz? (Importance of resistance testing…) Still NNRTI as support to Combivir/Truvada/Kivexa in 1 st line, or maybe Fosamprenavir/Reyataz? (Importance of resistance testing…) Emphasise that all PIs to be boosted? (Unlike US) Emphasise that all PIs to be boosted? (Unlike US) BHIVA Guidelines What’s new:

Presently deals with drugs now in use such as Enfuvirtide, Atazanavir, Tenofovir Presently deals with drugs now in use such as Enfuvirtide, Atazanavir, Tenofovir New drugs to be looked at include the new PIs TMC114 and Tipranavir, New drugs to be looked at include the new PIs TMC114 and Tipranavir, The new RTI Reverset (D-D4FC) The new RTI Reverset (D-D4FC) The new NNRTI TMC125 The new NNRTI TMC125 BHIVA Guidelines, New Drugs:

Shown to be effective in a PI experienced population with resistant virus Shown to be effective in a PI experienced population with resistant virus 50 people randomised. After 8 weeks of treatment the median difference in VL and absolute drop in VL among people switching to TMC114/RTV significantly exceeded VL changes in people staying with the same PI 50 people randomised. After 8 weeks of treatment the median difference in VL and absolute drop in VL among people switching to TMC114/RTV significantly exceeded VL changes in people staying with the same PI Monika Peeters CROI 2004 abstract 533 Monika Peeters CROI 2004 abstract 533 a new boosted PI New Drugs: TMC114 a new boosted PI

RESIST1 and RESIST 2 Different continents; similar results - promising RESIST1 and RESIST 2 Different continents; similar results - promising Evaluated the efficacy and safety of TPV/Ritonavir(RTV) in comparison to 4 different RTV-boosted PIs Evaluated the efficacy and safety of TPV/Ritonavir(RTV) in comparison to 4 different RTV-boosted PIs People with multiple PI resistance mutations had better virological outcomes on Tipranavir 34% vs. 13%with VL<400; 23% vs. 9%<50 People with multiple PI resistance mutations had better virological outcomes on Tipranavir 34% vs. 13%with VL<400; 23% vs. 9%<50 Expanded access in UK. Launched this year Expanded access in UK. Launched this year Pedro Cahn: Foundación Huesped, Buenos Aires, Argentina, PL14.3 RESIST 2: phase 3 study, Glasgow 7 th International Congress on Drug Therapy in HIV Infection Pedro Cahn: Foundación Huesped, Buenos Aires, Argentina, PL14.3 RESIST 2: phase 3 study, Glasgow 7 th International Congress on Drug Therapy in HIV Infection a new boosted PI New Drugs: Tipranavir a new boosted PI

Low mitochondrial toxicity O/D drug Low mitochondrial toxicity O/D drug May have activity against many viral strains with NRTI resistance May have activity against many viral strains with NRTI resistance 10 day trial Small numbers; 10 treatment experienced people with VL>1000 enrolled. 2 given placebo 10 day trial Small numbers; 10 treatment experienced people with VL>1000 enrolled. 2 given placebo 7/8 had VL drop of at least 0.5 log 4 with VL below 400. Next phase sees 180 recruited 7/8 had VL drop of at least 0.5 log 4 with VL below 400. Next phase sees 180 recruited 44th ICAAC (Slide H-1130) Tolerance and anti-HIV-1 activity of Reverset following 10 days as add-on therapy to current regimens in treatment experienced HIV-infected individuals: RL Murphy et al 44th ICAAC (Slide H-1130) Tolerance and anti-HIV-1 activity of Reverset following 10 days as add-on therapy to current regimens in treatment experienced HIV-infected individuals: RL Murphy et al 44th ICAAC Tolerance and anti-HIV-1 activity of Reverset following 10 days as add-on therapy to current regimens in treatment experienced HIV-infected individuals 44th ICAAC Tolerance and anti-HIV-1 activity of Reverset following 10 days as add-on therapy to current regimens in treatment experienced HIV-infected individuals a new RTI New Drugs: Reverset a new RTI

Drugs in this class have problems with cross resistance Drugs in this class have problems with cross resistance TMC 125 could be used against viral strains with NNRTI resistance TMC 125 could be used against viral strains with NNRTI resistance Brian Gazzard’s (1) 7 day substitution study on16 people with efavirenz resistance showed at day 7, the median decrease in viral load was -0.9 log from baseline Brian Gazzard’s (1) 7 day substitution study on16 people with efavirenz resistance showed at day 7, the median decrease in viral load was -0.9 log from baseline In vitro data from CROI 2001 (2) showed high activity against key resistant strains such as K103N In vitro data from CROI 2001 (2) showed high activity against key resistant strains such as K103N 1.Gazzard B et al. abstract 5, TMC125, a Next-Generation NNRTI, Demonstrates High Potency after 7 Days Therapy in Treatment-Experienced HIV-1-Infected Individuals with Phenotypic NNRTI Resistance. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, Gazzard B et al. abstract 5, TMC125, a Next-Generation NNRTI, Demonstrates High Potency after 7 Days Therapy in Treatment-Experienced HIV-1-Infected Individuals with Phenotypic NNRTI Resistance. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, Gruzdev B et al. Abstract I-668. TMC125 is a highly potent non-nucleoside reverse transcriptase inhibitor (NNRTI) in antiretroviral therapy (ART)-naive, HIV-1 infected subjects. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, Ill. 2.Gruzdev B et al. Abstract I-668. TMC125 is a highly potent non-nucleoside reverse transcriptase inhibitor (NNRTI) in antiretroviral therapy (ART)-naive, HIV-1 infected subjects. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, Ill. a new NNRTI New Drugs: TMC125 a new NNRTI

Other new drugs under investigation such as the CXCR4 and CCR5 antagonists are not sufficiently advanced to be dealt with yet. (They’re also not so well supported by Brian Gazzard!) Thanks for your attention: Brian West contact details: Tel: Other new drugs under investigation such as the CXCR4 and CCR5 antagonists are not sufficiently advanced to be dealt with yet. (They’re also not so well supported by Brian Gazzard!) Thanks for your attention: Brian West contact details: Tel: